Related Experiment Video

Updated: Jul 20, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Targeted Oncology
|August 5, 2023
PubMed

Insights

Darolutamide significantly improved overall survival in men with metastatic hormone-sensitive prostate cancer when combined with standard therapy. This oral androgen receptor inhibitor demonstrated a manageable safety profile, expanding treatment options.

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Metastatic hormone-sensitive prostate cancer (mHSPC) remains a significant clinical challenge.
  • Androgen receptor inhibitors (ARi) are crucial in managing prostate cancer progression.
  • Existing treatment paradigms for mHSPC often involve combination therapies.

Purpose of the Study:

  • To evaluate the efficacy and safety of darolutamide (NUBEQA®) in combination with androgen deprivation therapy (ADT) and docetaxel for mHSPC.
  • To assess darolutamide's impact on overall survival and secondary endpoints in a pivotal trial.
  • To determine the tolerability profile of darolutamide when added to ADT and docetaxel.

Main Methods:

  • A pivotal clinical trial comparing darolutamide plus ADT and docetaxel against placebo plus ADT and docetaxel.
  • Primary endpoint focused on overall survival.
  • Evaluation of secondary endpoints and adverse events to assess treatment outcomes and safety.

Main Results:

  • Darolutamide plus ADT and docetaxel demonstrated superiority in prolonging overall survival compared to placebo.
  • Improvements were observed in most secondary endpoints, indicating broader clinical benefit.
  • The combination therapy exhibited a manageable tolerability profile, consistent with known ADT and docetaxel safety.

Conclusions:

  • Darolutamide offers a valuable addition to the treatment armamentarium for mHSPC.
  • The drug shows promise, particularly for patients with high-volume disease.
  • Expanded treatment options with darolutamide enhance therapeutic strategies for mHSPC.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K